Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Sophia Bielesch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Technical University of Munich, Germany. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Ovarian Neoplasms, Keratin-19, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung.
Abstract (Originalsprache)
High‐grade serous ovarian cancer (HGSOC) is the most prevalent and lethal subtype of epithelial ovarian cancer (EOC), characterised by extensive peritoneal metastasis. The intermediate filament keratin 19 (KRT19) has been linked to tumour progression and chemoresistance in various cancers. However, its role varies across tumour types and remains unclear for HGSOC. We evaluated KRT19 protein expression in 199 HGSOC patients and correlated findings with clinical outcomes. In vitro , we assessed the effects of KRT19 on tumour‐associated mechanisms, including proliferation, migration, adhesion, and spheroid formation. A xenograft mouse model was used to assess tumour burden in vivo . Publicly available datasets enabled in silico validation. KRT19 was significantly overexpressed in HGSOC, and high expression was associated with reduced overall survival. In vivo , KRT19‐overexpression increased peritoneal tumour burden. In vitro and ex vivo , KRT19 induced a hybrid epithelial phenotype through enhanced epithelial–mesenchymal plasticity (EMP), promoting adhesion, migration, and spheroid integrity, thereby potentially supporting metastatic processes. Further, KRT19 could contribute to paclitaxel resistance. Altogether, KRT19 represents a potential independent prognostic marker and therapeutic target to inhibit metastatic dissemination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynaecology and Obstetrics, Technical University of Munich, Germany.
- Faculty of Medicine, Institute for Surgical Pathology, Medical Centre, University of Freiburg, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between DKFZ and Technical University of Munich, Heidelberg, Germany.
ORCID-Profile: Sophia Bielesch, Oliver Schilling
Förderung
- Wilhelm Sander-Stiftung
Zitieren
APA
Bielesch, S., Vogel, I., Nokodian, S., Moeller, J., Blechschmidt, A., Hecht, V., Kuentzel, V., Thiedig, K., Schwab, M., Schilling, O., Bronger, H., Kiechle, M., Magdolen, V., & Dreyer, T. (2026). Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70227
Vancouver
Bielesch S, Vogel I, Nokodian S, Moeller J, Blechschmidt A, Hecht V, et al. Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer. Molecular Oncology. 2026. doi:10.1002/1878-0261.70227
BibTeX
@article{Bielesch2026,
author = {Bielesch, Sophia and Vogel, Isabel and Nokodian, Sina and Moeller, Johanna and Blechschmidt, Antonia and Hecht, Vicky and Kuentzel, Vanessa and Thiedig, Katharina and Schwab, Melissa and Schilling, Oliver and Bronger, Holger and Kiechle, Marion and Magdolen, Viktor and Dreyer, Tobias},
title = {Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70227}
}
EUVIMED